Ultragenyx Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study for Wilson Disease with AAV9 Gene Therapy

In Stage 1, 15 patients received varying doses of UX701, and six have completely stopped their standard treatment, with copper levels normalizing in these patients. A seventh patient is currently in the process of tapering off. UX701 was well-tolerated with no unexpected safety concerns or major immunological events. Ultragenyx is now planning to introduce an additional cohort in Stage 1 with a moderately higher dose and optimized immunomodulation to boost the therapy’s efficiency.

Dr. Eric Crombez, Chief Medical Officer at Ultragenyx, expressed optimism, saying, “The clinical activity we’re observing, alongside a number of patients transitioning off standard treatments, gives us confidence that UX701 could represent a novel treatment for people with Wilson disease. Enhancing the dose and immunomodulation could potentially allow more patients to discontinue current treatments.”

Study Design

The Cyprus2+ study is divided into three stages. Stage 1 focuses on evaluating the safety and efficacy of multiple UX701 dose levels to determine the optimal dose for further stages. To date, 15 patients have been enrolled across three dose cohorts. In the upcoming Stage 2, a randomized trial will evaluate the selected dose against a placebo. Patients will continue to be monitored in Stage 3 for long-term effects.

About Wilson Disease

Wilson disease is a rare genetic disorder caused by mutations in the ATP7B gene, leading to abnormal copper accumulation in the liver and other organs. Patients experience hepatic, neurological, and psychiatric symptoms that can worsen over time, resulting in severe liver disease or even death. Current treatments, including lifelong chelation therapy, aim to reduce copper buildup but are not without limitations. Wilson disease affects over 50,000 individuals globally.

About UX701

UX701 is an investigational gene therapy using an AAV9 vector to deliver the ATP7B copper transporter. Preclinical studies have shown its potential to restore copper trafficking and balance within the body. UX701 has been granted Orphan Drug Designation in the U.S. and EU, and Fast Track Designation in the U.S.

For more information, visit Ultragenyx’s website or Ultragenyx clinical trials page.

This update highlights the promising future of UX701 as a potential treatment option for Wilson disease, addressing unmet needs and offering hope to patients affected by this rare disorder.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services